Development of MUC1 vaccine for the prevention of pancreatic cancer

Ended Awarded Last action

Contract number
HHSN26100005
Awardee
Awarding agency
Obligated
$398,683

Award facts

Opportunity
Contract value 100% obligated
$398,683.32 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Oklahoma City, OK 73104, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 7 $0
Other Administrative Action 6 -$236
Other Administrative Action 5 $0
Other Administrative Action 4 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Other Administrative Action 3 · Preclinical efficacy and intermediate endpoint biomarkers: development of MUC1 vaccine for the prevention of pancreatic cancer $0
Original award $398,919

Quick answers

Who was awarded contract HHSN26100005?

HHSN26100005 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 18, 2013.

How much is contract HHSN26100005 worth?

The government has obligated $398,683 on HHSN26100005.

Is contract HHSN26100005 an order under another contract?

Yes. HHSN26100005 is a delivery order under HHSN261201200013I, an indefinite delivery contract, on Preclinical Efficacy and Intermediate Endpoint Biomarkers.

Was contract HHSN26100005 competed?

The extent of competition for HHSN26100005 was full and open competition. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login